Company news: Pfizer, IMS Health and ElsevierA Phase II trial showed that Pfizer's tofacitinib looks like it could be a contender for the ulcerative colitis market. The study surveyed 194 adults who received between 0.5 mg and 15 mg of the drug or a placebo over the course of eight weeks and found a clinical response at the eight-week mark. The findings were published Thursday in the New England Journal of Medicine. The pill is currently awaiting FDA approval for treating rheumatoid arthritis.
IMS Health acquired TTC, a Philadelphia-based clinical trial benchmarking and analytics firm. Terms were not disclosed. TTC's tools aim to enhance the speed, efficiency and cost-effectiveness of pharma's clinical trial planning and management activities. Clients include 17 of the top 20 pharmaceutical companies and eight of the ten largest contract research organizations, according to a statement.Elsevier launched a new journal, Performance Enhancement & Health. The international, peer-reviewed journal critically explores the health implications of performance enhancement, “from steroid doping in elite athletes, right through to amphetamine use amongst truck drivers,” according to a statement from the publisher. The quarterly title will appeal to healthcare workers, as well as social scientists and those working in physical or sporting fields, Elsevier said.